{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"100.1","value":"196.6"},{"groupId":"OG001","spread":"482.9","value":"99.9"},{"groupId":"OG002","spread":"383.0","value":"145.7"},{"groupId":"OG003","spread":"355.1","value":"105.1"},{"groupId":"OG004","spread":"3312.4","value":"46.5"},{"groupId":"OG005","spread":"328.3","value":"115.4"},{"groupId":"OG006","spread":"165.2","value":"267.4"},{"groupId":"OG007","spread":"234.5","value":"126.9"},{"groupId":"OG008","spread":"184.1","value":"142.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"11"},{"groupId":"OG001","value":"27"},{"groupId":"OG002","value":"29"},{"groupId":"OG003","value":"22"},{"groupId":"OG004","value":"12"},{"groupId":"OG005","value":"27"},{"groupId":"OG006","value":"13"},{"groupId":"OG007","value":"30"},{"groupId":"OG008","value":"29"}],"units":"Participants"}],"dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Participants with cervical cancer with HER2 amplification/over expression, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG000","title":"Tucatinib+Trastuzumab (Cohort 1)"},{"description":"Participants with uterine cancer with HER2 amplification/over expression, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG001","title":"Tucatinib+Trastuzumab (Cohort 2)"},{"description":"Participants with biliary tract cancer with HER2 amplification/over expression, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG002","title":"Tucatinib+Trastuzumab (Cohort 3)"},{"description":"Participants with urothelial cancer with HER2 amplification/over expression, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG003","title":"Tucatinib+Trastuzumab (Cohort 4)"},{"description":"Participants with NSCLC with HER2 amplification/over expression, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG004","title":"Tucatinib+Trastuzumab (Cohort 5)"},{"description":"Participants with solid tumor types (except breast, gastric or GEC, and CRC) with HER2 amplification/over expression, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG005","title":"Tucatinib+Trastuzumab (Cohort 6)"},{"description":"Participants with non-squamous NSCLC with HER2 mutations, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG006","title":"Tucatinib+Trastuzumab (Cohort 7)"},{"description":"Participants with breast cancer with HER2 mutations, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants with hormone-receptor positive breast cancer also received fulvestrant 500 mg IM once every 4 weeks starting from Day 1 of Cycle 1, and on Day 15 of Cycle 1. Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG007","title":"Tucatinib+Trastuzumab+ Fulvestrant (Cohort 8)"},{"description":"Participants with all solid tumor cancers (except breast and non-squamous NSCLC) with HER2 mutations, received tucatinib 300 mg PO BID from Day 1 of Cycle 1 onwards and trastuzumab 8 mg/kg IV on Day 1 of Cycle 1 and then 6 mg/kg every 21 days starting on Day 1 of Cycle 2 (1 Cycle = 21 Days). Participants received treatment until unacceptable toxicity, occurrence of radiographic progression or clinical progression, withdrawal of consent, death, or study closure.","id":"OG008","title":"Tucatinib+Trastuzumab (Cohort 9)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK analysis set included all participants in the safety set from whom at least one evaluable PK assessment was reported.","reportingStatus":"POSTED","timeFrame":"Cycle 3 Day 1: Predose","title":"Trough Concentration (Ctrough) of Tucatinib","type":"SECONDARY","unitOfMeasure":"Nanogram per milliliter"}